Why the Richest Man Alive Lives in a $50,000 Shack

The result landed Friday evening and the U.S. market is closed until Tuesday. That gap matters, because what Novartis and Ionis disclosed on September 4 is not a minor pipeline stumble. It is the collapse of the foundational premise behind an entire drug class.

Novartis announced that pelacarsen failed the pivotal Phase 3 Lp(a)HORIZON trial, failing to reduce the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared with placebo. Pelacarsen did lower Lp(a) as expected. That drop simply did not translate into fewer heart attacks or strokes. Six years of trial execution, 8,323 patients, and a biomarker that moved exactly as intended, none of it was enough.

What Each Company Loses

Novartis had a great deal riding on the outcome, as pelacarsen was one of a handful of prospects it had hoped might offset a wave of patent expirations for key products. Analysts at William Blair estimated $6 billion in peak annual U.S. sales alone if the drug had succeeded. That figure is now zero. The loss is one more pressure point as Novartis navigates patent expirations and the post-generic decline in Entresto in the U.S.

For Ionis, the financial damage is direct. Under its licensing arrangement with Novartis, Ionis was entitled to tiered royalties in the mid-teens to low 20 percent range on net sales, plus $650 million in development, regulatory, and commercial milestones. A failed outcomes trial eliminates the commercial royalty stream entirely and almost certainly voids the portion of milestones tied to approval and launch. This is also the second cardiovascular outcomes disappointment this year for Ionis, following a miss in a transthyretin-mediated amyloid cardiomyopathy trial disclosed July 9.

In aftermarket trading Friday, U.S.-listed Novartis shares declined about 4% to 5% while Ionis fell about 12%, according to Reuters. Neither stock has had a full session to reset. Tuesday’s open is where analysts will be forced to mark their models to reality.

The Read-Through Hits the Entire Class

Citi analyst Geoff Meacham said the first dedicated outcomes failure lowers confidence across the class and places greater pressure on later studies to demonstrate that deeper lowering of Lp(a) can produce a clinically meaningful reduction of major cardiovascular events.

Other experimental Lp(a)-lowering drugs in development include Amgen’s olpasiran and Eli Lilly’s lepodisiran, both of which are in late-stage development. Silence Therapeutics is also advancing a drug that uses a different method to stop genes from making Lp(a) particles. Amgen shares slipped about 5% after-hours on the news. All three companies now face investor pressure to explain why their molecule should behave differently.

Amgen has said olpasiran reduced Lp(a) by 95% or more in Phase 2 testing at higher doses. A William Blair note on Friday warned the negative results suggest there is meaningful risk in other ongoing trials. The argument from Amgen and Lilly bulls will be that deeper Lp(a) suppression achieves what pelacarsen’s roughly 80% reduction could not. That argument is now a hypothesis requiring proof, not an assumption analysts should bake into price targets.

Forward Scenarios Before Tuesday

Bull: Full data presented at an upcoming medical congress reveal a subgroup of patients with very high baseline Lp(a) who did benefit, preserving a narrower label possibility and partially rehabilitating the class hypothesis. Novartis pipeline assets including ianalumab and radioligand therapies absorb enough of the attention that NVS holds near prior levels. IONS recovers modestly on its wholly owned commercial drugs, including the recently FDA-approved ZANVASTRO.

Base: Pelacarsen is shelved permanently. Novartis takes a target cut of 10 to 15 percent from street estimates tied to cardiovascular pipeline value. Ionis loses roughly 15 to 20 percent of sell-side price targets as royalty and milestone projections are stripped out. AMGN and LLY absorb narrower but real target reductions as investors adjust outcome-trial risk for olpasiran and lepodisiran.

Bear: The gap between surrogate biomarker reduction and clinical outcomes creates a fundamental hurdle for drug developers, forcing regulatory agencies and trial sponsors to re-examine whether lowering Lp(a) is a reliable surrogate endpoint at all. In this case, AMGN and LLY abandon or restructure late-stage programs, erasing years of pipeline premium from both stocks.

What Investors Should Watch Tuesday

• Full data release date: The companies said full trial data will be presented at an upcoming medical congress. The specific congress and date will determine how long the uncertainty window stays open.
• Subgroup disclosures: Citi analyst Geoff Meacham noted that full trial data are needed to determine whether the miss reflects pelacarsen’s mechanism of action, inadequate Lp(a) reduction, trial design, or fundamental doubts that lowering Lp(a) reduces heart disease risk.
• AMGN and LLY analyst notes: Watch for revised probability-of-success assumptions on olpasiran and lepodisiran. Any firm cutting POS below 40 percent is pricing in class failure.
• Ionis guidance reiteration: Management’s commentary on its wholly owned commercial portfolio will determine how much of the IONS selloff reverses versus sticks.

Bottom Line

The HORIZON failure does not prove that Lp(a) lowering can never prevent heart attacks. It proves that lowering Lp(a) by roughly 80% in an outcomes trial of 8,323 patients did not. That is the only Phase 3 cardiovascular outcomes data point the market has. Every bull case for AMGN, LLY, and SLN now rests on the premise that deeper lowering, a different molecular mechanism, or a better-selected patient population will produce what pelacarsen could not. Analysts who keep full pipeline credit in their models without adjusting outcome-trial risk are not being optimistic. They are ignoring the only Phase 3 cardiovascular outcomes readout this class has produced so far.